1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 8,600 | 8,620 | 13:52 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.05. | SMAIO Reported Revenue of €2.8 Million in the First Quarter of 2026, an Increase of 11% | 359 | Business Wire | Revenue in the United States reached a record quarterly high of €2.3 million (+21%), or $2.6 million (+35%)1 excluding currency effects
The United States accounts for nearly 80% of the... ► Artikel lesen | |
| 11.05. | SMAIO Expands Its North American Scientific Advisory Board With a New Renowned Surgeon | 321 | Business Wire | Appointment of Dr. Jeffrey M. Hills, an orthopedic surgeon specializing in complex spinal conditions SMAIO's Scientific Advisory Board, now comprised of five members, is a key asset in... ► Artikel lesen | |
| 05.05. | SMAIO Announces that Portzamparc (BNP Paribas Group) has Initiated Coverage of its Stock with a Buy Rating | 451 | Business Wire | Regulatory News:
SMAIO (Software, Machines and Adaptive Implants in Orthopaedics Euronext Growth Paris, ISIN Code: FR0014005I80 Ticker: ALSMA), a French-American company specialized in complex... ► Artikel lesen | |
| 06.03. | SMAIO Announces a €3.6 Million Capital Increase to Support Its Long-Term Growth Momentum | 497 | Business Wire | Capital increase totaling €3.6 million gross through the issuance of shares with stock warrants (ABSAs) at a price of €7 per share
4 warrants will entitle the holder to subscribe for one... ► Artikel lesen | |
| 20.01. | SMAIO Reports 2025 Sales of €9.2m, Representing an Increase of +67% | 417 | Business Wire | U.S. sales rose by +138% to €7m, and by +160% to $7.9m (excluding currency effects).
Strong growth across North American centers that were already active in 2024 (+130%). 11 new... ► Artikel lesen | |
| 08.01. | SMAIO: 2026 Financial Calendar | 516 | Business Wire | Regulatory News:
SMAIO (Software, Machines and Adaptive Implants in Orthopaedics Euronext Growth Paris, ISIN: FR0014005I80 Ticker: ALSMA), a French-American player specialized in complex spine... ► Artikel lesen | |
| 06.01. | SMAIO Obtains €2.0m in Non-Dilutive Financing | 483 | Business Wire | €1.0m in the form of a 0% interest loan co-financed by the European Union, the Auvergne-Rhône-Alpes Region and Bpifrance, with a repayment deferral period of two and a half years €1.0m... ► Artikel lesen | |
| S.M.A.I.O SA Aktie jetzt für 0€ handeln | |||||
| 19.12.25 | SMAIO Successfully Continues Its Think Tanks Focused on Promoting Its Innovative Solutions in the United States | 662 | Business Wire | New attendance record at the New York session, bringing together nearly 60 experts from the spine sector, including over 40 surgeons
Regulatory News:
SMAIO (Software, Machines and Adaptative... ► Artikel lesen | |
| 24.11.25 | SMAIO Appoints Matthieu Ville as Chief Commercial Officer to Accelerate Commercialization and Strengthen Its Leadership in Spinal Realignment | 363 | Business Wire | Matthieu Ville brings over 15 years of experience in medical marketing in the United States.
Regulatory News:
SMAIO (Software, Machines and Adaptative Implants in Orthopaedics- Euronext Growth... ► Artikel lesen | |
| 03.11.25 | SMAIO Adds a New High-Profile Member to Its Scientific Advisory Board in the United States | 377 | Business Wire | Appointment of Dr. Tenner Guillaume, Orthopaedic spine surgeon who specializes in spinal deformity at Gillette Children's Hospital (St. Paul, Minnesota). SMAIO's US scientific advisory board... ► Artikel lesen | |
| 22.10.25 | SMAIO Signs a New Distribution Agreement for Its Open Platform KEOPS-4ME With Orthofix in the U.S. | 559 | Business Wire | Orthofix is a global medical technology company focused on healing musculoskeletal pathologies The distribution arrangement is part of SMAIO's collaborative strategy aimed at deploying... ► Artikel lesen | |
| 14.10.25 | SMAIO Announces Strong First-Half 2025 Results and Robust Growth in Business Activity in the Third Quarter of 2025 | 362 | Business Wire | Strong sales growth in H1 2025: +126% to €5.0 million
Increase in gross margin in H1 2025 to 85% vs. 64% in H1 2024
Significant improvement in EBITDA (+96%) reaching break-even (vs.... ► Artikel lesen | |
| 24.09.25 | SMAIO Signs the First Major Distribution Agreement for Its Open Platform KEOPS-4ME with Highridge Medical in the U.S. | 456 | Business Wire | Highridge Medical is one of the world's largest privately held spine companies The partnership represents a key milestone in further expanding SMAIO's business activity in the U.S. and driving... ► Artikel lesen | |
| 16.07.25 | SMAIO Announces Significant Sales Increase in H1 2025 | 453 | Business Wire | Sales H1 2025: +126% to €5 million Acceleration of business activity in the United States (+360% to €3.8 million):
H1 2025 sales1 higher than full-year 2024 sales
More than... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BRIGHTSPRING HEALTH SERVICES | 69,63 | -0,01 % | Raymond James initiates BrightSpring Health stock with outperform rating | ||
| HEARTFLOW | 26,160 | 0,00 % | Heartflow, Inc.: New Data at SCCT 2026 Reinforce Heartflow Plaque Analysis as the Standard for AI-Powered Coronary Artery Disease Management | ||
| BILLIONTOONE | 123,25 | 0,00 % | BillionToOne, Inc.: BillionToOne Reports Fourth Quarter and Full Year 2025 Results and Raises 2026 Revenue Guidance | MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 34,370 | -3,35 % | UBS stuft Siemens Healthineers auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat das Kursziel für Siemens Healthineers von 51 auf 38 Euro gesenkt, aber die Einstufung auf "Neutral" belassen. Mehrere Risikofaktoren belasteten... ► Artikel lesen | |
| FRESENIUS | 41,225 | -1,12 % | DAX nach Rekord tiefer: Börsen-Beben in Südkorea - Bayer, Rheinmetall, Fresenius und Kion ... | Beim deutschen Leitindex zeichnet sich am Dienstag ein schwächerer Start in den Handelstag ab. Schlechte Vorgaben aus Asien belasten den DAX. Während der Nikkei zur Stunde rund zwei Prozent verliert... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 20,380 | 0,00 % | Kaplan Fox & Kilsheimer LLP: Kaplan Fox Alerts Investors of Alignment Healthcare, Inc. (ALHC) to an Investigation of Potential Securities Law Violations | New York, New York--(Newsfile Corp. - July 10, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Alignment Healthcare, Inc. ("Alignment Healthcare" or... ► Artikel lesen | |
| PROGYNY | 31,990 | +0,03 % | KeyBanc raises Progyny stock price target on utilization strength | ||
| CARL ZEISS MEDITEC | 29,420 | -6,78 % | BERNSTEIN RESEARCH stuft CARL ZEISS MEDITEC AG auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat Carl Zeiss Meditec mit einem Kursziel von 26,10 Euro auf "Market-Perform" belassen. Dies schrieb Analystin Susannah Ludwig am... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 42,400 | -1,26 % | JPMORGAN stuft FMC FRESENIUS MEDICAL CARE AG auf 'Underweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat FMC auf "Underweight" mit einem Kursziel von 37,40 Euro belassen. Aus neuesten Daten zu Nierenerkrankungen im Endstadium gehe hervor, dass immer... ► Artikel lesen | |
| ONCOLOGY INSTITUTE | 6,250 | 0,00 % | BTIG hebt Kursziel für Oncology Institute Aktie nach Umschuldung auf 9 US-Dollar an | ||
| BETA BIONICS | 16,960 | +0,06 % | Beta Bionics, Inc.: Beta Bionics Announces First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance | IRVINE, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial... ► Artikel lesen | |
| PRIVIA HEALTH GROUP | 27,890 | 0,00 % | Privia Health Group, Inc. - 8-K, Current Report | ||
| GENEDX | 63,81 | -0,06 % | Piper Sandler raises GeneDx stock price target on coverage policy | ||
| LIFESTANCE HEALTH GROUP | 10,875 | -0,05 % | LifeStance Health Group, Inc. - 8-K, Current Report | ||
| PROCEPT BIOROBOTICS | 21,240 | +0,09 % | PROCEPT BioRobotics Reports First Quarter 2026 Financial Results | SAN JOSE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen |
Das Unternehmen S.M.A.I.O SA kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 8,600 Euro und damit +3,37 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu S.M.A.I.O SA finden Sie auf Wallstreet Online.